Bupredale

Main information

  • Trade name:
  • Bupredale
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Bupredale
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • buprenorphine
  • Therapeutic area:
  • Cats, Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0270/001
  • Authorization date:
  • 10-01-2008
  • EU code:
  • UK/V/0270/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:March2011

Amendedpages

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFVETERINARYMEDICINALPRODUCT

Buprenodale0.3mg/mlsolutionforinjectionfordogsandcats.(AT,BE,BU,CZ,DE,

FR,HU,IE,LU,NL,PL,SK,UK)

BuprenodaleVet0.3mg/mlsolutionforinjectionfordogsandcats.(DK,FI,IS,SE)

Budale0.3mg/mlsolutionforinjectionfordogsandcats.(ES,IT,PT)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Each1mlampoulecontains:

ActiveSubstance(s)

Buprenorphine0.3mgasbuprenorphinehydrochloride.

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection.

Clear,colourlesssolution.

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogsandcats

4.2 Indicationsforuse,specifyingthetargetspecies

Post-operativeanalgesiainthecatanddog.

Potentiationofthesedativeeffectsofcentrallyactingagentsinthedog.

4.3 Contra-indications

Theproductshouldnotbeusedpre-operativelyforcaesariansection(seesection

4.7).

4.4 Specialwarningsforeachtargetspecies

None

4.5 Specialprecautionsforuse

i.Specialprecautionsforuseinanimals

Revised:March2011

Amendedpages

Buprenorphinemayoccasionallycauserespiratorydepressionandaswithother

opioiddrugs,careshouldbetakenwhentreatinganimalswithimpairedrespiratory

functionoranimalsthatarereceivingdrugsthatcancauserespiratorydepression.

Asbuprenorphineismetabolisedbytheliver,itsintensityanddurationofaction

maybeaffectedinanimalswithimpairedliverfunction.

Incaseofrenal,cardiacorhepaticdysfunction,orshock,theremaybegreaterrisk

associatedwiththeuseoftheproduct.Thebenefit:riskratioforusingtheproduct

shouldbemadebytheattendingvet.Safetyhasnotbeenfullyevaluatedinclinically

compromisedcats.

Thesafetyofbuprenorphinehasnotbeendemonstratedinanimalslessthan7

weeksofage,thereforeuseinsuchanimalsshouldbebasedonthebenefit:risk

assessmentoftheveterinarian.

Repeatedadministrationearlierthantherecommendedrepeatintervalsuggested

inSection4.9isnotrecommended.

Theeffectofanopioidonheadinjuryisdependentonthetypeandseverityofthe

injuryandtherespiratorysupportsupplied.Theproductshouldbeusedin

accordancewiththebenefit:riskassessmentoftheattendingveterinarian.

ii.Specialprecautionstobetakenbythepersonadministeringthemedicinalproduct

toanimals

Asbuprenorphinehasopioid-likeactivity,careshouldbetakentoavoidaccidental

self-injection.

Incaseofaccidentalself-injectionoringestion,seekmedicaladviceimmediately

andshowthepackageleafletorthelabeltothephysician.

Followingeyecontaminationorskincontact,washthoroughlywithcoldrunning

water.Seekmedicaladviceifirritationpersists.

4.6 Adversereactions(frequencyandseriousness)

Salivation,bradycardia,hypothermia,agitation,dehydrationandmiosiscanoccurin

thedog,andrarelyhypertensionandtachycardia.

Mydriasisandsignsofeuphoria(excessivepurring,pacing,rubbing)commonlyoccur

incatsandwillusuallyresolvewithin24hours.

Buprenorphinemayoccasionallycausesignificantrespiratorydepression;referto

section4.5i).

Whenusedtoprovideanalgesia,sedationmayappearasanadversereaction.

4.7 Useduringpregnancy,lactationorlay

Pregnancy:

Laboratorystudiesinratshavenotproducedanyevidenceofateratogeniceffect.

However,thesestudieshaveshownpost-implantationlossesandearlyfoetaldeaths.

Revised:March2011

Amendedpages

Asreproductivestudieshavenotbeenconductedintargetanimals,useonlyaccording

tothebenefit:riskassessmentbytheresponsibleveterinarian.

Theproductshouldnotbeusedpre-operativelyincasesofCaesareansection,dueto

theriskofrespiratorydepressionintheoffspringperiparturiently,andshouldonlybe

usedpost-operativelywithspecialcare(seesectiononlactationbelow).

Lactation:

Studiesinlactatingratshaveshownthat,afterintramuscularadministrationof

buprenorphine,concentrationsofunchangedbuprenorphineinthemilkequalledor

exceededthatintheplasma.Asitislikelythatbuprenorphinewillbeexcretedinthe

milkofotherspecies,useisnotrecommendedduringlactation.Useonlyaccordingly

tobenefit:riskassessmentbytheresponsibleveterinarian.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Thereisevidenceinhumanstoindicatethattherapeuticdosesofbuprenorphinedo

notreducetheanalgesicefficacyofstandarddosesofanopioidagonist,andthat

whenbuprenorphineisemployedwithinthenormaltherapeuticrange,standarddoses

ofopioidagonistmaybeadministeredbeforetheeffectsoftheformerhaveended

withoutcompromisinganalgesia.However,itisrecommendedthatbuprenorphineis

notusedinconjunctionwithmorphineorotheropioid-typeanalgesics,e.g.etorphine,

fentanyl,pethidine,methadone,papaveretumorbutorphanol.

Buprenorphinehasbeenusedwithacepromazine,alphaxalone/alphadalone,atropine,

halothane,isoflurane,ketamine,medetomidine,propofol,sevoflurane,thiopentoneand

xylazinewithoutanyobservedadverseeffects.

Buprenorphinemaycausesomedrowsiness,whichmaybepotentiatedbyother

centrally-actingagents,includingtranquillisers,sedativesandhypnotics.

4.9 Amountstobeadministeredandadministrationroute

Forintramuscularuse.

Species Post-OperativeAnalgesia Potentiationofsedative

effects

Dog 10 –20microgramperkg(0.3–0.6mlper10kg)

repeatedifnecessaryafter3 –4hourswith10

microgramor5 –6hourswith20microgram

doses. 10 –20microgramperkg(0.3–

0.6mlper10kg).

Cat 10 –20microgramperkg(0.3–0.6mlper10kg),

repeatedifnecessary,once,after2hours.

Toensurethatanalgesiaispresentimmediatelyonrecovery,theproductcanbe

administeredpreoperatively(seesection5.2).Pharmacologicaleffectsoccurwithin30

minutesafterinjection.Ifadditionalanalgesiaissubsequentlyrequired,thismaybe

achievedbyadministrationofafurtherdoseofBuprenorphineorconcomitantuseofa

suitableinjectableNSAID.

Revised:March2011

Amendedpages

Anappropriatelygraduatedsyringemustbeusedtoallowaccuratedosing.Thisis

particularlyimportantwheninjectingsmallvolumes.

Whenadministeredpre-operativelyinconjunctionwithotherpremedicants,itmaybe

possibletoreducetheamountofpremedicant,suchasacepromazineor

medetomidine,andalsotheamountofinhalationalanaestheticused.

Animalsadministeredopioidspossessingsedativeandanalgesicpropertiesmay

showvariableresponses.Therefore,theresponsesofindividualanimalsshouldbe

monitoredandsubsequentdosesadjustedaccordingly.Insomecasesrepeatdoses

mayfailtoprovideadditionalanalgesia.Inthesecases,considerationshouldbegiven

tousingasuitableinjectableNSAID.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary.

Whenadministeredatoverdosetodogs,buprenorphinemaycauselethargy.Atvery

highdoses,bradycardiaandmiosismaybeobserved.

Incasesofoverdosage,supportivemeasuresshouldbeinstituted,and,ifappropriate,

naloxoneorrespiratorystimulantsmaybeused. However,doselevelsmanytimes

higherthanthoseindicatedabovehavebeenusedwithoutserioussideeffects.

Naloxonemaybeofbenefitinreversingreducedrespiratoryrateandrespiratory

stimulantssuchasDoxapramarealsoeffectiveinman.Becauseoftheprolonged

durationofeffectofbuprenorphineincomparisontosuchdrugs,theymayneedtobe

administeredrepeatedlyorbycontinuousinfusion.

Volunteerstudiesinmanhaveindicatedthatopiateantagonistsmaynotfullyreverse

theeffectsofbuprenorphine.

PleasealsorefertoSections4.5.i)and4.6ofthisSPC.

4.11Withdrawalperiods

Notapplicable.

5. PHARMACOLOGICALPARTICULARS

Pharmacotherapeuticgroup:Opioidanalgesics,oripavinederivatives

ATCvetcode:QN02AE01.

5.1 Pharmacodynamicproperties

Insummarybuprenorphineisapotent,long-actinganalgesicactingatopiatereceptors

inthecentralnervoussystem.

Buprenorphineexertsitsanalgesiceffectviahighaffinitybindingtovarioussubclasses

ofopiatereceptors,particularlyµ,inthecentralnervoussystem.Atclinicaldoselevels

foranalgesia,buprenorphinedemonstrateshighefficacyandbindstoopiatereceptors

withhighaffinityandhighreceptoravidity,suchthatitsdissociationfromthereceptor

siteisslow,asdemonstratedininvitrostudies.Thisuniquepropertyofbuprenorphine

Revised:March2011

Amendedpages

couldaccountforitslongerdurationofactivitywhencomparedtomorphine.In

circumstanceswhereexcessiveopiateagonistisalreadyboundtoopiatereceptors,

buprenorphinecanexertanarcoticantagonisticactivityasaconsequenceofitshigh-

affinityopiatereceptorbinding,suchthatanantagonisticeffectonmorphineequivalent

tonaloxonehasbeendemonstrated.

5.2 Pharmacokineticparticulars

Buprenorphineisrapidlyabsorbedafterintramuscularinjectioninvariousanimal

speciesandman.Thesubstanceishighlylipophilicandthevolumeofdistributionin

bodycompartmentsislarge.Inthecat,pharmacologicaleffectsoccurwithin30

minutesafterinjectionandpeakeffectsareusuallyobservedatabout1 –1.5hours.

Followingintramuscularadministrationtocats,themeanterminalhalf-lifewas6.3

hoursandtheclearancewas23ml/kg/min,however,therewasconsiderableinter-cat

variabilityinpharmacokineticparameters.

Norelevantpharmacokineticdataareavailableinthedog.

Combinedpharmacokineticandpharmacodynamicstudiesincatshavedemonstrated

amarkeddelaybetweenplasmaconcentrationsandanalgesiceffect.Plasma

concentrationsofbuprenorphineshouldnotbeusedtoformulateindividualanimal

dosageregimens,whichshouldbedeterminedbymonitoringofthepatient’s

response.

Themajorrouteofexcretioninallspeciesexcepttherabbit(whereurinaryexcretion

predominates)isthefaeces.BuprenorphineundergoesN-dealkylationand

glucuronideconjugationbytheintestinalwallandtheliveranditsmetabolitesare

excretedviathebileintothegastro-intestinaltract.

Intissuedistributionstudiescarriedoutinratsandrhesusmonkeysthehighest

concentrationsofdrug-relatedmaterialwereobservedinliver,lungandbrain.Peak

levelsoccurredrapidlyanddeclinedtolowlevelsby24hoursafterdosing.

Proteinbindingstudiesinratshaveshownthatbuprenorphineishighlyboundto

plasmaproteins,principallytoalphaandbetaglobulins.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Glucoseanhydrous

Sodiumhydroxide(pHadjustment)

Hydrochloricacid(pHadjustment)

Waterforinjection

6.2 Incompatibilities

Noneknown.

6.3 Shelf-life

Revised:March2011

Amendedpages

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:5years

Theproductdoesnotcontainanantimicrobialpreservative.Anysolutionremainingin

anampoulefollowingwithdrawaloftherequireddoseshouldbediscarded.

6.4 Specialprecautionsforstorage

Donotstoreabove25°C.Keeptheampouleintheoutercartoninordertoprotectfrom

light.

Donotrefrigerateorfreeze.

6.5 Natureandcompositionofimmediatepackaging

Cardboardcartoncontainingfive1ml colourlessTypeIglass‘snap’topampoules.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts,ifappropriate

Anyunusedproductorwastematerialshouldbedisposedofinaccordancewith

nationalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

DechraLimited

DechraHouse,

JamageIndustrialEstate,

TalkePits,

Stoke-on-Trent

ST71XW.

UK.

8. MARKETINGAUTHORISATIONNUMBER(S)

Vm10434/4035

9. DATEOFFIRSTAUTHORISATION

17February2009

10. DATEOFREVISIONOFTHETEXT

March2011

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

21-9-2018

Pending EC decision:  Buvidal, buprenorphine, Opinion date: 20-Sep-2018

Pending EC decision: Buvidal, buprenorphine, Opinion date: 20-Sep-2018

Europe - EMA - European Medicines Agency

7-9-2018

FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence

FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence

FDA approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence.

FDA - U.S. Food and Drug Administration

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

14-6-2018

FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence

FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence

: FDA approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) for the treatment of opioid dependence.

FDA - U.S. Food and Drug Administration

28-11-2018

Econor (Elanco GmbH)

Econor (Elanco GmbH)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8038 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/42/T/54

Europe -DG Health and Food Safety

26-11-2018

Wakix (Bioprojet Pharma)

Wakix (Bioprojet Pharma)

Wakix (Active substance: Pitolisant hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7974 of Mon, 26 Nov 2018

Europe -DG Health and Food Safety

22-11-2018

Buvidal (Camurus AB)

Buvidal (Camurus AB)

Buvidal (Active substance: buprenorphine) - Centralised - Authorisation - Commission Decision (2018)7879 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4651

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Active substance: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride) - Orphan designation - Commission Decision (2018)7791 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/040/18

Europe -DG Health and Food Safety

13-11-2018

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7576 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/233/16/T/01

Europe -DG Health and Food Safety

13-11-2018

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7575 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/140/13/T/01

Europe -DG Health and Food Safety

1-11-2018

Dexdomitor (Orion Corporation)

Dexdomitor (Orion Corporation)

Dexdomitor (Active substance: dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7380 of Thu, 01 Nov 2018

Europe -DG Health and Food Safety

31-10-2018

Evista (Daiichi Sankyo Europe GmbH)

Evista (Daiichi Sankyo Europe GmbH)

Evista (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7342 of Wed, 31 Oct 2018

Europe -DG Health and Food Safety

26-9-2018

Sileo (Orion Corporation)

Sileo (Orion Corporation)

Sileo (Active substance: Dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)6325 of Wed, 26 Sep 2018

Europe -DG Health and Food Safety

10-8-2018

Brinavess (Correvio)

Brinavess (Correvio)

Brinavess (Active substance: vernakalant hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5523 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1215/T/31

Europe -DG Health and Food Safety

6-8-2018

Bosulif (Pfizer Europe MA EEIG)

Bosulif (Pfizer Europe MA EEIG)

Bosulif (Active substance: Bosutinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5372 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2373/T/32

Europe -DG Health and Food Safety

30-7-2018

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Active substance: ertugliflozin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5103 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4314/T/2

Europe -DG Health and Food Safety

30-7-2018

Ceplene (Noventia Pharma Srl)

Ceplene (Noventia Pharma Srl)

Ceplene (Active substance: Histamine dihydrochloride) - Centralised - Renewal - Commission Decision (2018)5116 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/796/R/36

Europe -DG Health and Food Safety

23-7-2018

Optruma (Eli Lilly Nederland B.V.)

Optruma (Eli Lilly Nederland B.V.)

Optruma (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4893 of Mon, 23 Jul 2018

Europe -DG Health and Food Safety

12-7-2018

Econor (Elanco Europe Ltd)

Econor (Elanco Europe Ltd)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4580 of Thu, 12 Jul 2018

Europe -DG Health and Food Safety

11-7-2018

Ariclaim (Eli Lilly Nederland B.V.)

Ariclaim (Eli Lilly Nederland B.V.)

Ariclaim (Active substance: duloxetine hydrochloride) - Centralised - Withdrawal - Commission Decision (2018)4515 of Wed, 11 Jul 2018

Europe -DG Health and Food Safety

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency

3-7-2018

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4254 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/896/T/90

Europe -DG Health and Food Safety

3-7-2018

Ristfor (Merck Sharp and Dohme B.V.)

Ristfor (Merck Sharp and Dohme B.V.)

Ristfor (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4249 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1235/T/77

Europe -DG Health and Food Safety

3-7-2018

Velmetia (Merck Sharp and Dohme B.V.)

Velmetia (Merck Sharp and Dohme B.V.)

Velmetia (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4252 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/862/T/93

Europe -DG Health and Food Safety

3-7-2018

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4251 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/861/T/90

Europe -DG Health and Food Safety

29-6-2018

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (Active substance: (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride) - Orphan designation - Commission Decision (2018)4173 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/003/18

Europe -DG Health and Food Safety

14-6-2018

Kuvan (BioMarin International Limited)

Kuvan (BioMarin International Limited)

Kuvan (Active substance: sapropterin dihydrochloride) - Centralised - Yearly update - Commission Decision (2018)3859 of Thu, 14 Jun 2018

Europe -DG Health and Food Safety

13-6-2018

Suboxone (Indivior Europe Limited)

Suboxone (Indivior Europe Limited)

Suboxone (Active substance: buprenorphine / naloxone) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3632 of Wed, 13 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/697/T/38

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3809 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/092/10/T/03

Europe -DG Health and Food Safety